Mechanisms of Action
How Ibogaine & Noribogaine Work
Five clinician-grade deep-dives into the molecular targets, signaling cascades, and pharmacokinetics that explain why a single supervised flood-dose can produce sustained anti-craving and mood-stabilizing effects long after the parent drug clears.
Quick Answer
How does ibogaine work?
Reviewed by Dr. Arellano, M.D. — May 2026
BDNF & GDNF Upregulation
Ibogaine and noribogaine upregulate brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), driving downstream neuroplasticity and dopaminergic repair.
Mu-Opioid Receptor
Ibogaine and noribogaine interact with the mu-opioid receptor at low affinity — but the clinical effect on opioid withdrawal is multifactorial, not a simple substitute-and-taper.
NMDA Receptor Antagonism
Ibogaine is a non-competitive NMDA receptor antagonist — a mechanism it shares with ketamine, dextromethorphan, and memantine, with implications for tolerance reversal and dissociative experience.
Ibogaine Pharmacokinetics
Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination — including the long noribogaine tail that drives the post-flood telemetry window.
Noribogaine — The Long-Tail Metabolite
Noribogaine is ibogaine's CYP2D6-formed metabolite — cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.
Methodological Note
These are mechanism explainers, not personal medical advice.
The clinical evidence base for ibogaine is substantially smaller than for FDA-approved medications. Where receptor and signaling data are extrapolated from rodent or in-vitro work, we say so explicitly. For human-clinical context, see the 2026 evidence base review and the onsite taper cohort methodology page.